Explores Super-GDF9's impact on oocyte maturation and blastocyst formation in women with polycystic ovary syndrome, suggesting no improvement was observed.
Introduction: This pilot study determined the effect of adding Super-GDF9 to capacitation in-vitro maturation (CAPA-IVM) culture media on oocyte maturation and blastocyst formation. Methods: The study was conducted at an academic infertility center in Vietnam in January–February 2025. Cumulus-oocyte complexes (COCs) were obtained from consenting subfertile women aged 18–35 years who had polycystic ovary syndrome, ≥30 COCs at oocyte pick-up (OPU) in a CAPA-IVM cycle, and were willing to donate ≥10 COCs for research purposes. COCs from sibling human oocytes were treated without (control) or with Super-GDF9 (50 ng/mL) added to CAPA-IVM capacitation and maturation cultures. All metaphase II (MII) oocytes were inseminated using intracytoplasmic sperm injection. The primary endpoint was proportion of blastocysts at end of culture (per patient/per COCs). Results: For per-patient outcomes, only the median [interquartile range] rate of good-quality blastocysts per total blastocysts differed significantly between the Super-GDF9 (0.0 [0.0, 0.0]) and control (83.3 [16.7, 100.0]) groups (effect size [95% confidence interval) –50.0 [–100.0, 0.0]; p=0.02). There were no good-quality blastocysts in the Super-GDF9 group. The rate of blastocysts (per COCs and per day-3 embryos) tended to be lower in the Super-GDF9 group. Conclusions: Adding Super-GDF9 to the current CAPA-IVM protocol did not improve blastocyst formation and showed a trend toward lower blastocyst formation, which requires confirmation in adequately powered studies.
No takes yet. Share an insight, caveat, or question.
Vuong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: